A mitochondrial RNA switch helps lymphoma cells refuse to die — turning it down restored cell death — in lab models

The team at Guangzhou First People's Hospital (Xu, Wang, He and colleagues) had previously found that phosphorylated CYLD regulates apoptosis in rituximab-resistant DLBCL. This study asked whether a long non-coding RNA controls that switch — and traced the answer to the mitochondrial surface, where the cell's death decision is executed.

How did the team find the SNHG29 axis?

They built rituximab-resistant DLBCL models by dose escalation, measured mitochondrial dysfunction through reactive-oxygen-species flux, and combined RNA sequencing with computational and biochemical analyses. CYLD emerged as an apoptotic hub and SNHG29 as a resistance mediator; mitochondrial subfractionation, co-immunoprecipitation and lentiviral perturbation experiments then mapped how the two interact through ribosomal proteins, with the transcription factor NF-kappaB involved in regulating the axis.

What happened when SNHG29 was turned down?

Down-regulating SNHG29 reduced phosphorylated CYLD on the mitochondria and promoted apoptosis in the resistant cells — the death program the tumor had been evading. The mechanism was validated preclinically in xenograft mouse models and in clinical specimens, which showed high phosphorylated CYLD involved in DLBCL tumorigenesis, progression and rituximab resistance.

Is this a new lymphoma drug?

No — it is a newly mapped target. No SNHG29-directed therapy exists, RNA-targeting drugs face delivery challenges, and CYLD biology is context-dependent across cancers. What the study adds is a precise address: a mitochondrially localized RNA-protein axis that resistant lymphoma cells depend on, which is the kind of address drug developers need before a therapy can be designed.

Where the evidence stands

• Established: DLBCL is the most common aggressive non-Hodgkin lymphoma; rituximab resistance worsens prognosis, and mitochondrial apoptosis control is central to how lymphoma cells evade treatment.
• Preliminary: In resistant DLBCL cell models, mouse xenografts and clinical specimens (Scientific Reports, Oct 20, 2026), the SNHG29-RPS-CYLD axis was mitochondrially localized, high phosphorylated CYLD tracked with resistance, and down-regulating SNHG29 lowered mitochondrial phosphorylated CYLD and restored apoptosis.
• Absent: Any SNHG29- or CYLD-targeting therapy, human trial data, or evidence the axis can be drugged safely.